Safety and efficacy of induction immunochemotherapy with rituximab, methotrexate, ifosfamide, and vincristine (R-MIV) in patients with primary CNS lymphoma including recent COVID-19 pandemic experience
© 2023 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd..
Clinical data on primary central nervous system (CNS) lymphoma (PCNSL) patients is mostly generated from prospective studies, and many frail real-world patients are not included. Recently,the diagnosis and treatment of PCNSL patients was confounded by the COVID-19 pandemic. In particular, treatment with high-dose cytarabine was linked to increased risk of pneumonia and virus persistence. We report on outcome of the induction regimen R-MIV (rituximab, methotrexate, ifosfamide, and vincristine) involving intensive administration of high-dose methotrexate (3.5 g/m2 ) with ifosfamide, every 2 weeks and rituximab once per week for six doses. The median age and performance status (PS) for 64 patients was 58 years and 2 (PS 3; 22%) respectively. The overall response rate by magnetic resonance imaging/computed tomography (MRI/CT) was 73% (n = 46/63), with an additional 17.5% (n = 11/63) patients without measurable disease at baseline. Grade 3-4 haematological toxicity was low for R-MIV (neutropenia: 25% and thrombocytopenia: 1%). Three patients (4.7%) died from treatment-related toxicity. Co-existence of SARS-CoV-2 infection with cytomegalovirus reactivation and the varicella-zoster virus in two patients was fatal. Fifty patients (78%) were eligible for consolidation. Median progression-free and overall survival were not reached (median follow-up: 44 months). In conclusion, the R-MIV regimen is feasible in routine practice, effective and safe, even during the COVID-19 pandemic.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:201 |
|---|---|
| Enthalten in: |
British journal of haematology - 201(2023), 4 vom: 28. Mai, Seite 663-672 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ostrowska, Beata [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
04079A1RDZ |
|---|
| Anmerkungen: |
Date Completed 04.05.2023 Date Revised 11.05.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/bjh.18687 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM352724919 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM352724919 | ||
| 003 | DE-627 | ||
| 005 | 20231226054359.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/bjh.18687 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1175.xml |
| 035 | |a (DE-627)NLM352724919 | ||
| 035 | |a (NLM)36762710 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ostrowska, Beata |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Safety and efficacy of induction immunochemotherapy with rituximab, methotrexate, ifosfamide, and vincristine (R-MIV) in patients with primary CNS lymphoma including recent COVID-19 pandemic experience |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.05.2023 | ||
| 500 | |a Date Revised 11.05.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd. | ||
| 520 | |a Clinical data on primary central nervous system (CNS) lymphoma (PCNSL) patients is mostly generated from prospective studies, and many frail real-world patients are not included. Recently,the diagnosis and treatment of PCNSL patients was confounded by the COVID-19 pandemic. In particular, treatment with high-dose cytarabine was linked to increased risk of pneumonia and virus persistence. We report on outcome of the induction regimen R-MIV (rituximab, methotrexate, ifosfamide, and vincristine) involving intensive administration of high-dose methotrexate (3.5 g/m2 ) with ifosfamide, every 2 weeks and rituximab once per week for six doses. The median age and performance status (PS) for 64 patients was 58 years and 2 (PS 3; 22%) respectively. The overall response rate by magnetic resonance imaging/computed tomography (MRI/CT) was 73% (n = 46/63), with an additional 17.5% (n = 11/63) patients without measurable disease at baseline. Grade 3-4 haematological toxicity was low for R-MIV (neutropenia: 25% and thrombocytopenia: 1%). Three patients (4.7%) died from treatment-related toxicity. Co-existence of SARS-CoV-2 infection with cytomegalovirus reactivation and the varicella-zoster virus in two patients was fatal. Fifty patients (78%) were eligible for consolidation. Median progression-free and overall survival were not reached (median follow-up: 44 months). In conclusion, the R-MIV regimen is feasible in routine practice, effective and safe, even during the COVID-19 pandemic | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a HD-MTX | |
| 650 | 4 | |a PCNSL, primary CNS lymphoma | |
| 650 | 4 | |a remission induction | |
| 650 | 7 | |a Methotrexate |2 NLM | |
| 650 | 7 | |a YL5FZ2Y5U1 |2 NLM | |
| 650 | 7 | |a Rituximab |2 NLM | |
| 650 | 7 | |a 4F4X42SYQ6 |2 NLM | |
| 650 | 7 | |a Ifosfamide |2 NLM | |
| 650 | 7 | |a UM20QQM95Y |2 NLM | |
| 650 | 7 | |a Vincristine |2 NLM | |
| 650 | 7 | |a 5J49Q6B70F |2 NLM | |
| 650 | 7 | |a Cytarabine |2 NLM | |
| 650 | 7 | |a 04079A1RDZ |2 NLM | |
| 700 | 1 | |a Domanska-Czyz, Katarzyna |e verfasserin |4 aut | |
| 700 | 1 | |a Romejko-Jarosinska, Joanna |e verfasserin |4 aut | |
| 700 | 1 | |a Osowiecki, Michal |e verfasserin |4 aut | |
| 700 | 1 | |a Targonski, Lukasz |e verfasserin |4 aut | |
| 700 | 1 | |a Poplawska, Lidia |e verfasserin |4 aut | |
| 700 | 1 | |a Konecki, Robert |e verfasserin |4 aut | |
| 700 | 1 | |a Kotarska, Martyna |e verfasserin |4 aut | |
| 700 | 1 | |a Szymanski, Marcin |e verfasserin |4 aut | |
| 700 | 1 | |a Borawska, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Swierkowska, Monika |e verfasserin |4 aut | |
| 700 | 1 | |a Dabrowska-Iwanicka, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Druzd-Sitek, Agnieszka |e verfasserin |4 aut | |
| 700 | 1 | |a Paszkiewicz-Kozik, Ewa |e verfasserin |4 aut | |
| 700 | 1 | |a Mroz-Zycinska, Ewa |e verfasserin |4 aut | |
| 700 | 1 | |a Tajer, Joanna |e verfasserin |4 aut | |
| 700 | 1 | |a Wojciechowska-Lampka, Elzbieta |e verfasserin |4 aut | |
| 700 | 1 | |a Osiadacz, Wlodzimierz |e verfasserin |4 aut | |
| 700 | 1 | |a Rymkiewicz, Grzegorz |e verfasserin |4 aut | |
| 700 | 1 | |a Lapinska, Grazyna |e verfasserin |4 aut | |
| 700 | 1 | |a Wojewodzka-Mirocha, Marta |e verfasserin |4 aut | |
| 700 | 1 | |a Michalski, Wojciech |e verfasserin |4 aut | |
| 700 | 1 | |a Walewski, Jan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t British journal of haematology |d 1955 |g 201(2023), 4 vom: 28. Mai, Seite 663-672 |w (DE-627)NLM000000396 |x 1365-2141 |7 nnns |
| 773 | 1 | 8 | |g volume:201 |g year:2023 |g number:4 |g day:28 |g month:05 |g pages:663-672 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/bjh.18687 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 201 |j 2023 |e 4 |b 28 |c 05 |h 663-672 | ||